Elizabeth Alli

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
    Elizabeth Alli
    Stanford University School of Medicine, Department of Medicine Oncology, 269 Campus Drive, Stanford, CA 93405, USA
    DNA Repair (Amst) 11:522-4. 2012
  2. pmc Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
    Elizabeth Alli
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA 94305, USA
    BMC Pharmacol 11:7. 2011
  3. pmc Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin
    Kedar Hastak
    Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 70:7970-80. 2010
  4. doi request reprint A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013
  5. pmc Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 69:3589-96. 2009
  6. pmc Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California
    Cancer Res 74:6205-15. 2014

Collaborators

Detail Information

Publications6

  1. doi request reprint Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
    Elizabeth Alli
    Stanford University School of Medicine, Department of Medicine Oncology, 269 Campus Drive, Stanford, CA 93405, USA
    DNA Repair (Amst) 11:522-4. 2012
    ..In conclusion, BRCA1-mutated and/or basal-like breast cancers may benefit from treatment regimens that include elesclomol...
  2. pmc Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
    Elizabeth Alli
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA 94305, USA
    BMC Pharmacol 11:7. 2011
    ..BRCA1 plays a role in multiple DNA repair pathways, and thus, when mutated, results in sensitivity to certain DNA damaging drugs...
  3. pmc Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin
    Kedar Hastak
    Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 70:7970-80. 2010
    ..Our results suggest a novel therapeutic strategy to treat women with TN breast cancer, an aggressive disease that presently lacks effective treatment options...
  4. doi request reprint A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013
    ..The results are inconclusive and do not exclude a favorable effect on breast cancer risk. ..
  5. pmc Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 69:3589-96. 2009
    ..The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness...
  6. pmc Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California
    Cancer Res 74:6205-15. 2014
    ..This work offers a preclinical proof-of-concept for a wholly new approach to chemoprevention in carriers of BRCA1 mutations as a strategy to reduce the prevalence of BRCA1-associated malignancy...